Patient and donor characteristics grouped by CD34+ cell dose
| . | 1 × 106/kg to 3 × 106/kg n = 28 . | > 3 × 106/kg n = 56 . | P . |
|---|---|---|---|
| Follow-up (median in months) | 34 | 18 | .001 |
| Follow-up of living patients | 43 | 27 | .004 |
| Sex-pairing match | 14 (50%) | 39 (70%) | .09 |
| Donors, median age | 39.6 | 40.4 | .8 |
| Recipients, median age | 39.5 | 41.6 | .35 |
| CMV serology | |||
| D and R negative | 7 (25%) | 10 (18%) | .6 |
| D negative | 12 (42.9%) | 22 (39.3%) | .8 |
| R negative | 11 (39.2%) | 14 (25%) | .3 |
| Diagnosis | |||
| AML/ALL/MDS | 15 (53.6%) | 29 (52%) | |
| CML | 5 (17.8%) | 14 (25%) | |
| NHL/CLL/MM | 7 (25%) | 13 (23.2%) | |
| Hist X | 1 (3.6%) | 0 (0%) | .8 |
| Early stage of disease | 17 (60.7%) | 43 (77%) | .1 |
| Median of CD3+ cells × 106/kg | 0.3 | 0.3 | .8 |
| . | 1 × 106/kg to 3 × 106/kg n = 28 . | > 3 × 106/kg n = 56 . | P . |
|---|---|---|---|
| Follow-up (median in months) | 34 | 18 | .001 |
| Follow-up of living patients | 43 | 27 | .004 |
| Sex-pairing match | 14 (50%) | 39 (70%) | .09 |
| Donors, median age | 39.6 | 40.4 | .8 |
| Recipients, median age | 39.5 | 41.6 | .35 |
| CMV serology | |||
| D and R negative | 7 (25%) | 10 (18%) | .6 |
| D negative | 12 (42.9%) | 22 (39.3%) | .8 |
| R negative | 11 (39.2%) | 14 (25%) | .3 |
| Diagnosis | |||
| AML/ALL/MDS | 15 (53.6%) | 29 (52%) | |
| CML | 5 (17.8%) | 14 (25%) | |
| NHL/CLL/MM | 7 (25%) | 13 (23.2%) | |
| Hist X | 1 (3.6%) | 0 (0%) | .8 |
| Early stage of disease | 17 (60.7%) | 43 (77%) | .1 |
| Median of CD3+ cells × 106/kg | 0.3 | 0.3 | .8 |
CMV indicates cytomegalovirus; D, donor; R, recipient; AML, acute myeloblastic leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodisplastic syndrome; CML, chronic myeloid leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; MM, multiple myeloma; Hist X, histiocytosis X.